Systemic virotherapy using oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes

2015 Fiscal Year Final Research Report

• Project/Area Number: 25293275
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Nagoya University
• Principal Investigator: KASUYA Hideki 名古屋大学, 医学(系)研究科(研究院), 准教授 (00402636)
• Co-Investigator(Kenkyū-buntansha): KODERA Yasuhiro 名古屋大学, 医学系研究科, 教授 (10345879) ; UCHIDA Hiroaki 東京大学, 医科学研究所, 講師 (20401250) ; YAMADA Suguru 名古屋大学, 医学部附属病院, 病院講師 (30467287) ; SHIKU Hiroshi 三重大学, 医学系研究科, 産学連携講座教員 (80154194) ; NOMOTO Shuji 名古屋大学, 医学部附属病院, 病院講師 (40300967)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: HF10 / 腫瘍溶解性ウイルス / 悪性黒色腫 / ヒッチハイクメソッド / リンパ球療法 / Drug delivery

Outline of Final Research Achievements

In this study, we investigated the possibility of systemic administration of HF10 adsorbed on the tumor antigen-specific lymphocytes. We administered adsorbed HF10 to the tail vein of mice with subcutaneous tumor expressed ovalbumin antigen and analyzed the efficacy of this treatment. HF10 absorbed on ovalbumin antigen-specific T cells showed significant antitumor effect more than control group. Our results suggest that HF10 adsorbed on tumor antigen-specific lymphocytes could be delivered systemically without interference of host immune response, and it have significant potential in treatment of the disseminated tumors. We acquired precious basic data for clinical trial.

Free Research Field

消化器外科学